V-Set and immunoglobulin domain containing (VSIG) proteins as emerging immune checkpoint targets for cancer immunotherapy

The development of immune checkpoint inhibitors is becoming a promising approach to fight cancers. Antibodies targeting immune checkpoint proteins such as CTLA-4 and PD-1 can reinvigorate endogenous antitumor T-cell responses and bring durable advantages to several malignancies. However, only a smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xia, Khan, Sohail, Huang, Dabing, Li, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520664/
https://www.ncbi.nlm.nih.gov/pubmed/36189222
http://dx.doi.org/10.3389/fimmu.2022.938470

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520664/
https://www.ncbi.nlm.nih.gov/pubmed/36189222
http://dx.doi.org/10.3389/fimmu.2022.938470

Ejemplares similares